Abstract
Concerns about the practicality and effectiveness of using Contact Tracing Apps (CTA) to reduce the spread of COVID19 have been well documented and, in the UK, led to the abandonment of the NHS CTA shortly after its release in May 2020. We present a causal probabilistic model (a Bayesian network) that provides the basis for a practical CTA solution that addresses some of the concerns and which has the advantage of minimal infringement of privacy. Users of the model can provide as much or little personal information as they wish about relevant risk factors, symptoms, and recent social interactions. The model then provides them feedback about the likelihood of the presence of asymptotic, mild or severe COVID19 (past, present and projected). When the model is embedded in a smartphone app, it can be used to detect new outbreaks in a monitored population and identify outbreak locations as early as possible. For this purpose, the only data needed to be centrally collected is the probability the user has COVID19 and the GPS location.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors acknowledge support from the EPSRC under project EP/P009964/1: PAMBAYESIAN: Patient Managed decision-support using Bayesian Networks and The Alan Turing Institute under the EPSRC grant EP/N510129/1. We also acknowledge the support of Agena.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NA
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Because the model and its web/phone implementation have been regularly updated, this paper does NOT describe the latest version.
The latest version of the Bayesian network model can be downloaded from: http://www.eecs.qmul.ac.uk/~norman/Models/covid19_for_web.cmpx The model can be run using the free trial version of AgenaRisk (www.agenarisk.com)
The model can also be run through a simple questionnaire interface over the web or on a mobile phone at https://covid19.apps.agenarisk.com/
Improvements made to the paper following reviewers' comments. The model has also been updated and improved with links provided to the latest version and its web implementation
3 The model described in the section is NOT the latest version. The latest version can be downloaded from: http://www.eecs.qmul.ac.uk/~norman/Models/covid19_for_web.cmpx and can be run using the free trial version of AgenaRisk (www.agenarisk.com)
8 Some of the limitations of the BN model described in this paper have been addressed in the latest version which can be downloaded from: http://www.eecs.qmul.ac.uk/~norman/Models/covid19_for_web.cmpx and run using the free trial version of AgenaRisk (www.agenarisk.com) The latest version of the model can also be run through a simple questionnaire interface over the web or on a mobile phone at https://covid19.apps.agenarisk.com/
Data Availability
Links are provided in the article to data and model
http://www.eecs.qmul.ac.uk/~norman/Models/covid19_for_contact_tracing_paper.cmpx